ERAS
13.95USD
-1.60 (-10.29%)
52-week high $24.28
52-week low $1.77
Erasca shares dropped 10.3 percent after rival Propanc Biopharma released data showing stronger results for its PRP treatment in pancreatic cancer compared with Erasca's ERAS-0015 program. The competitor's announcement weighed directly on the stock and added to its recent slide of 9.2 percent over the past five trading days. No broader market index move was cited in the available facts.
Propanc claims better PRP data vs Erasca's ERAS-0015
Propanc Biopharma Highlights Differentiated PRP Pancreatic Cancer Data Versus Emerging Pan-RAS Program ERAS-0015
The company is still unprofitable (net income is negative).
No significant trend signals detected. See the chart below.
Over the last 3 months it is about 27% behind the market — a clear lag.
The recent up-move has faded and selling pressure is stronger.
No standout or new-high signal. See trading details below.
A single day's movement doesn't change the long-term direction.
It's okay not to decide right now.
This content is compiled from publicly available data for reference only. It is not investment advice or a stock recommendation. All investment decisions and their outcomes are your own responsibility.